[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 12, 1974

Myeloproliferative Disorders: A New International Study

Author Affiliations

Chairman Polycythemia Vera Study Group Mt. Sinai Medical Center New York, NY 10029

JAMA. 1974;229(7):763. doi:10.1001/jama.1974.03230450013003

To the Editor.—  The Polycythemia Vera Study Group (PVSG) was organized seven years ago to better define the natural history of the disease, the optimal therapy, and the influence of the various therapeutic modalities on the course of the disease, particularly in development of myeloid metaplasia, myelofibrosis, and acute leukemia. Four hundred ten patients with polycythemia vera have already been entered into this randomized prospective study and are now being followed up.The PVSG has just instituted a major new protocol to study other myeloproliferative syndromes, exclusive of granulocytic leukemias. Previously untreated patients whose conditions were diagnosed as agnogenic myeloid metaplasia, myelofibrosis or sclerosis, primary thrombocytosis, or unclassificable myeloproliferative variants, will be enrolled for study. The purpose of this is to learn as much as possible about the pathophysiology of these disorders and to perform randomized therapeutic trials to determine the most effective therapy.Each patient will receive extensive diagnostic